Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Photocure ASA ( (PHCUF) ) has shared an announcement.
Photocure ASA reported record revenues for its Hexvix®/Cysview® products in the second quarter of 2025, driven by strong performance in the U.S. market and increased adoption of blue light cystoscopy technology. The company expects continued revenue growth and EBITDA improvement, with strategic expansions and partnerships, including a promising collaboration with Richard Wolf and a potential milestone from a license agreement with Asieris for Cevira in China.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, specializes in providing transformative solutions to enhance the lives of bladder cancer patients. Their unique technology, which causes cancer cells to glow bright pink, has improved health outcomes globally. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.
Average Trading Volume: 47,792
Current Market Cap: NOK1.68B
For an in-depth examination of PHCUF stock, go to TipRanks’ Overview page.